Lipocalin2 Expressions Correlate Significantly With Tumor Differentiation in Epithelial Ovarian Cancer
Lipocalin2 Expressions Correlate Significantly With Tumor Differentiation in Epithelial Ovarian Cancer
复制标题
DOI：
10.1369/jhc.2009.953257
复制
发表时间：
2009-05-01
影响因子：
3.2
通讯作者：
Kim, Jae-Hoon
中科院分区：
文献类型：
--
作者：
Cho, HanByoul;Kim, Jae-Hoon
我们最近发现脂质运载蛋白 2 (LCN2) 在卵巢癌细胞系中表达上调。本研究的目的是验证卵巢癌中 LCN2 的上调并研究其作为血清生物标志物的潜力。我们使用实时 PCR 和 IHC 检测了卵巢癌中的 LCN2 表达。为了评估 LCN2 作为生物标志物的潜力，我们测量了 54 例卵巢癌、15 例交界性卵巢肿瘤和 53 例良性卵巢肿瘤以及 90 例健康对照者的血清 LCN2 水平。 SYBR green PCR 和 IHC 显示 LCN2 在卵巢癌中过度表达。 LCN2 免疫反应性与肿瘤分化显着相关 (p=0.009)，因为分化良好的肿瘤显示出最高的 LCN2 表达。卵巢癌中的血清 LCN2 水平显着高于其他研究组 (p
We recently identified lipocalin2 (LCN2) as being upregulated in ovarian cancer cell lines. The purpose of this study was to validate LCN2 upregulation in ovarian cancers and to investigate its potential as a serum biomarker. We assayed LCN2 expression in ovarian cancers using real-time PCR and IHC. To evaluate the potential of LCN2 as a biomarker, we measured serum LCN2 levels in 54 ovarian cancers, 15 borderline and 53 benign ovarian tumors, and 90 healthy controls. SYBR green PCR and IHC showed LCN2 overexpression in ovarian cancers. LCN2 immunoreactivity was significantly associated with tumor differentiation (p=0.009), as well-differentiated tumors showed the highest LCN2 expression. Serum LCN2 level in ovarian cancer was significantly higher than in the other study groups (p